Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
Warning: file_get_contents(http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=20688889&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 500 Internal Server Error
in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 445
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Natalizumab (Tysabri) Selewski DT; Shah GV; Segal BM; Rajdev PA; Mukherji SKAJNR Am J Neuroradiol 2010[Oct]; 31 (9): 1588-90Natalizumab is a humanized IgG4kappa monoclonal antibody that is a selective adhesion molecule inhibitor, which prevents adhesion of leukocytes to endothelial cells. It is the first monoclonal antibody approved by the FDA for the treatment of relapsing-remitting MS. This article will review the mechanism of action and clinical role of this agent.|Animals[MESH]|Antibodies, Monoclonal, Humanized[MESH]|Antibodies, Monoclonal/*administration & dosage/*immunology[MESH]|Brain/drug effects/*immunology[MESH]|Cell Adhesion/drug effects/immunology[MESH]|Cell Migration Inhibition/drug effects/immunology[MESH]|Humans[MESH]|Leukocytes/drug effects/*immunology[MESH]|Models, Immunological[MESH]|Multiple Sclerosis/*drug therapy/*immunology[MESH]|Natalizumab[MESH] |
